Radiation plus immunotherapy for lung cancer that spread to the lung
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining a type of radiation therapy called SBRT with an immunotherapy drug called puterizumab for patients whose non-small cell lung cancer has spread to the lungs after prior immunotherapy. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that has spread to your lungs after previous treatment with immunotherapy (PD-1 inhibitors).
- You are willing to have a lung biopsy (a small sample taken from the lung) as part of the study.
- You are in generally good health (able to do daily activities with little help).
- Your blood test results meet certain levels for blood cells, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
This trial tests a new combination of radiation, immunotherapy, and chemotherapy given before surgery for stage II or III lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.